Radiotherapy After Breast Cancer: Is It Safe for Scleroderma Patients?
"Understanding the risks and benefits of radiotherapy for early breast cancer in women with scleroderma."
Adjuvant radiotherapy is a cornerstone in preventing local recurrence in women diagnosed with early-stage breast cancer. Clinical trials consistently demonstrate its effectiveness in reducing recurrence rates and enabling breast preservation. However, the use of radiotherapy in patients with connective vascular diseases (CVD), such as scleroderma, has been a topic of debate among researchers.
Scleroderma, a chronic autoimmune disease characterized by hardening and tightening of the skin and connective tissues, presents unique challenges when considering radiotherapy. Some researchers view it as a relative contraindication, while others consider it an absolute contraindication due to concerns about potential complications and adverse reactions. These concerns often revolve around the risk of increased fibrosis, retraction of the breast tissue, and heightened sensitivity to radiation-induced damage.
To address this uncertainty, a study was conducted to evaluate the safety and efficacy of postsurgical radiotherapy in women with pre-existing scleroderma who had been treated for early breast cancer. This article delves into the findings of this research, providing valuable insights for patients and healthcare professionals alike.
Radiotherapy as Standard Breast Cancer Care
Adjuvant radiotherapy is a key part of breast cancer management. The 2025 update reports that it is systematically recommended after breast-conserving surgery for invasive carcinoma, regardless of patient characteristics, because it reduces local recurrence and improves survival. It also says a tumour-bed boost is indicated for patients under 50; the snippet notes partial-breast irradiation as an option but does not specify its criteria. A regional NHS guideline says patients should generally be discussed at a multidisciplinary meeting before radiotherapy is offered, with a possible exception for urgent palliation in very frail or elderly patients with locally advanced disease.
A Long Evolution in Breast Cancer Treatment
Accounts of breast cancer treatment trace its history from ancient civilizations through the Middle Ages and the 18th and 19th centuries. One historical overview describes the 20th century as encompassing the advent of breast reconstruction, radiotherapy and chemotherapy, alongside advances in cancer biology. A separate timeline likewise presents treatment as having changed substantially since breast cancer was first recognized. The supplied summaries do not identify specific dates or individual discoveries.
Navigating Radiotherapy for Breast Cancer in Scleroderma Patients: Key Considerations and Findings
The study retrospectively reviewed the records of four patients with pre-existing scleroderma who underwent postoperative whole breast radiotherapy between May 1998 and November 2010. All patients had been diagnosed with early breast cancer and had undergone conservative surgery followed by radiotherapy. The radiotherapy regimen consisted of a total dose of 50.4 Gy to the whole breast, with an additional 9 Gy boost to the tumor bed.
- Early Skin Reactions: Two patients experienced grade 1 toxicity, characterized by mild skin changes, while one patient had grade 2 and another grade 3 toxicity.
- Late Toxicity: After a median follow-up of 105 months, one patient showed no late toxicity, two had grade 1 (slight atrophy), and one had grade 2 toxicity.
- Subcutaneous Tissue: Two patients had grade 1 toxicity, one had grade 2, and one had no toxicity.
- Lung and Heart: Only one patient developed grade 1 lung toxicity, with a minor increase in lung density noted on CT scans, but without clinical respiratory symptoms. No heart toxicity was observed in any patient.
Research on Techniques and Special-Case Management
A 2025 chapter surveys conventional breast cancer therapies and advanced radiotherapy techniques, including intensity-modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT) and proton beam therapy. A case report on breast cancer in a patient with pseudoxanthoma elasticum (PXE) says external radiotherapy could be contraindicated in that genetic disorder; in that case, intra-operative radiotherapy (IORT) was used as part of multidisciplinary management and helped avoid mastectomy. The supplied sources do not establish that these findings apply to scleroderma patients.
The Challenge of Late Effects
A 2025 review notes that even advanced radiotherapy technologies cannot completely prevent healthy tissues from receiving clinically significant incidental radiation doses. It says these exposures can contribute to considerable long-term morbidity and adversely affect quality of life. A review of late complications in breast cancer also frames long-term effects as an important concern as more patients survive for extended periods after treatment. The supplied material does not quantify these risks specifically for people with scleroderma.
Small Scleroderma Case Series and Technique Comparisons
In a four-case report of early breast cancer in patients with scleroderma, the median follow-up was 105 months, with a range of 12–155 months. The authors described early and late toxicity affecting skin, subcutaneous tissues, lungs and heart as acceptable and consistent with what had been reported in international literature. Separately, a study of whole-breast radiotherapy after breast-conserving surgery set out to compare seven techniques, including conventional tangential treatment. These sources address different questions, so the technique-comparison snippet does not corroborate the scleroderma case series’ toxicity findings.
Making Informed Decisions: A Multidisciplinary Approach to Breast Cancer Treatment in Scleroderma Patients
The study underscores the importance of a multidisciplinary tumor board in formulating personalized treatment strategies for patients with scleroderma and breast cancer. This collaborative approach ensures that all aspects of the patient's condition are considered, balancing therapeutic benefits with potential risks.
Expert Guidance on Treatment Integration
A consensus published June 25, 2026, describes rapid advances in radiotherapy techniques and systemic anticancer agents as creating opportunities to improve breast cancer outcomes, while raising challenges for their optimal integration and safety. A separate literature review presents expert opinion from the Institut Curie Breast Radiotherapy Group (IC-BRG) on integrating radiotherapy with modern systemic therapies. The therapies named include anti-HER2 and TROP2 antibody–drug conjugates, PARP inhibitors, CDK4/6 inhibitors and immunotherapies. The supplied summaries do not provide specific recommendations for scleroderma.
Research Priorities and Ongoing Trials
A 2023 bibliometric analysis examined global research trends and hot topics in breast cancer radiotherapy using Web of Science data. A 2026 overview from Susan G. Komen says research is ongoing to improve all areas of breast cancer treatment and that new therapies are being studied in clinical trials. It also identifies women treated with breast radiation many years ago who have small cancers that have not spread to lymph nodes as possible candidates for repeat radiation. The supplied material does not indicate whether those repeat-radiation criteria apply to patients with scleroderma.
Limited Guidance on Combining New Therapies
A source on concurrent new systemic therapies and radiotherapy describes the combination of radiotherapy with antibody-drug conjugates, immune checkpoint inhibitors and CDK4/6 inhibitors as creating new opportunities in breast cancer management. It also says clinical guidance on concurrent administration remains limited, particularly for advanced radiotherapy techniques. The source summary identifies integration and safety as central issues but supplies no specific guidance for patients with scleroderma.
When radiation therapy is deemed appropriate, it should be administered under specific conditions. These include the absence of systemic scleroderma, careful assessment of the patient's skin sensitivity to sunlight, optimal radiotherapy treatment planning to protect organs at risk (OARs) such as the lungs and heart, and the application of radiotherapy techniques tailored to the patient's anatomy. Thorough, day-by-day follow-up is also crucial to monitor and manage any potential side effects.
Ultimately, the decision to proceed with radiotherapy should be made in close collaboration with the patient, ensuring that she is fully informed about the potential benefits, risks, and expected outcomes. The patient's wishes and preferences should be central to the decision-making process, empowering her to make informed choices about her care.